Exchange: NYSE·Updated 04:25 AM EDT
News
all
press releases
GKOS Crosses Above Average Analyst Target
In recent trading, shares of Glaukos Corp (Symbol: GKOS) have crossed above the average analyst 12-month target price of $164.50, changing hands for $168.52/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valua...
Nasdaq News: Markets
More News
Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up
GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.
Zacks
Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of +50.00% and +24.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Glaukos Announces Second Quarter 2026 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include...
Business Wire
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO MicroShunt
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the...
Business Wire
Can ISRG Maintain Its Premium Valuation Amid Slower Procedure Growth?
Intuitive Surgical's valuation has eased as U.S. procedure growth slows, but margin gains, AI software expansion and global growth could support its premium.
Zacks
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?
Key PointsAlex R. Thurman generated ~$1.6 million in gross proceeds by selling 10,000 shares at $155 per share on July 9...
Nasdaq News: Markets
GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?
GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.
Zacks
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release second quarter 2026 financial results after the market close on Wednesday, July 29, 2026...
Business Wire

Advertisement|Remove ads.